Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

Exclusion Criteria

• •1. Hepatic encephalopathy that cannot be effectively treated.
• •2. Platelet transfusion within 7 days prior to the first dose of study drug
• •3. Received blood products, eg, FFP and cryoprecipitate 7 days prior to the first dose of study drug
• •4. Have surgical or diagnostic procedure scheduled during the Randomization Phase (Day 1 to Day 8) of this study
• •5. Interferon use within 2 weeks of Day 1
• •6. Hormonal contraceptive use within 60 days of study entry
• •7. History of human immunodeficiency virus (HIV) infection
• •8. Any prohibited concomitant medications or therapy that cannot be discontinued by Visit 1
• •9. Active alcohol abuse, active alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program)
• •10. Acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start
• •11. History of any primary hematologic disorder
• •12. History of arterial or venous thrombosis, including thrombosis of any part of the splenic-mesenteric system
• •13. Any evidence of current portal vein thrombosis (PVT) as detected by Doppler sonography or appropriate MRI/CT imaging at Screening and/or within approximately 30 days prior to Screening
• •14. Any acute/active bleeding (gastrointestinal \[GI\], central nervous system \[CNS\], etc)
• •15. Uncompensated congestive heart failure (New York Heart Association \[NYHA\] Class III or IV)
• •16. Pre-diagnosed Immune Thrombocytopenic Purpura (ITP)
• •17. History of Myelodysplastic Syndrome (MDS)
• •18. Females who are pregnant (positive β-hCG test ) or breastfeeding
• •19. Current use of recreational drugs
• •20. Post-transplant patients
• •21. Subjects who have participated in another investigational trial within 30 days prior to Visit 1.